GB201505239D0 - Antibody - Google Patents

Antibody

Info

Publication number
GB201505239D0
GB201505239D0 GBGB1505239.2A GB201505239A GB201505239D0 GB 201505239 D0 GB201505239 D0 GB 201505239D0 GB 201505239 A GB201505239 A GB 201505239A GB 201505239 D0 GB201505239 D0 GB 201505239D0
Authority
GB
United Kingdom
Prior art keywords
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1505239.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuro Bio Ltd
Original Assignee
Neuro Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuro Bio Ltd filed Critical Neuro Bio Ltd
Priority to GBGB1505239.2A priority Critical patent/GB201505239D0/en
Publication of GB201505239D0 publication Critical patent/GB201505239D0/en
Priority to GB1600871.6A priority patent/GB2541477A/en
Priority to KR1020177027589A priority patent/KR102626626B1/ko
Priority to RU2017133649A priority patent/RU2729491C2/ru
Priority to CA2979972A priority patent/CA2979972A1/en
Priority to MX2017012397A priority patent/MX392158B/es
Priority to PCT/GB2016/050804 priority patent/WO2016156803A1/en
Priority to ES16713029T priority patent/ES2952723T3/es
Priority to JP2017550514A priority patent/JP7327897B2/ja
Priority to US15/561,021 priority patent/US10954306B2/en
Priority to AU2016240020A priority patent/AU2016240020B2/en
Priority to EP16713029.3A priority patent/EP3274371B1/en
Priority to BR112017020769-9A priority patent/BR112017020769A2/en
Priority to CN201680021081.0A priority patent/CN107531796A/zh
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Psychology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
GBGB1505239.2A 2015-03-27 2015-03-27 Antibody Ceased GB201505239D0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
GBGB1505239.2A GB201505239D0 (en) 2015-03-27 2015-03-27 Antibody
GB1600871.6A GB2541477A (en) 2015-03-27 2016-01-18 Antibody
CN201680021081.0A CN107531796A (zh) 2015-03-27 2016-03-23 识别AChE的T14肽的抗体
PCT/GB2016/050804 WO2016156803A1 (en) 2015-03-27 2016-03-23 Antibody that recognises the t14 peptide of ache
RU2017133649A RU2729491C2 (ru) 2015-03-27 2016-03-23 Антитело, которое распознает пептид т14 асне
CA2979972A CA2979972A1 (en) 2015-03-27 2016-03-23 Antibody that recognises the t14 peptide of ache
MX2017012397A MX392158B (es) 2015-03-27 2016-03-23 Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache).
KR1020177027589A KR102626626B1 (ko) 2015-03-27 2016-03-23 Ache의 t14 펩타이드를 인식하는 항체
ES16713029T ES2952723T3 (es) 2015-03-27 2016-03-23 Anticuerpo que reconoce el péptido T14 de AChE
JP2017550514A JP7327897B2 (ja) 2015-03-27 2016-03-23 Acheのt14ペプチドを認識する抗体
US15/561,021 US10954306B2 (en) 2015-03-27 2016-03-23 Antibody that recognises the T14 peptide of AChE
AU2016240020A AU2016240020B2 (en) 2015-03-27 2016-03-23 Antibody that recognises the T14 peptide of AChE
EP16713029.3A EP3274371B1 (en) 2015-03-27 2016-03-23 Antibody that recognises the t14 peptide of ache
BR112017020769-9A BR112017020769A2 (en) 2015-03-27 2016-03-23 antibody or binding fragment, sequence no: 3 or sequence no: 7, antibody-drug conjugate (adc), pharmaceutical composition, process for producing the pharmaceutical composition, kit for diagnosing an individual suffering from a neurodegenerative disorder, method to diagnose an individual suffering from a neurodegenerative disorder, use of antibody or binding fragment, ex vivo use of a t14 peptide, method of identifying a candidate agent, method of identifying an agent, method of identifying a modulating agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1505239.2A GB201505239D0 (en) 2015-03-27 2015-03-27 Antibody

Publications (1)

Publication Number Publication Date
GB201505239D0 true GB201505239D0 (en) 2015-05-13

Family

ID=53178191

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB1505239.2A Ceased GB201505239D0 (en) 2015-03-27 2015-03-27 Antibody
GB1600871.6A Withdrawn GB2541477A (en) 2015-03-27 2016-01-18 Antibody

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB1600871.6A Withdrawn GB2541477A (en) 2015-03-27 2016-01-18 Antibody

Country Status (13)

Country Link
US (1) US10954306B2 (cg-RX-API-DMAC10.html)
EP (1) EP3274371B1 (cg-RX-API-DMAC10.html)
JP (1) JP7327897B2 (cg-RX-API-DMAC10.html)
KR (1) KR102626626B1 (cg-RX-API-DMAC10.html)
CN (1) CN107531796A (cg-RX-API-DMAC10.html)
AU (1) AU2016240020B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017020769A2 (cg-RX-API-DMAC10.html)
CA (1) CA2979972A1 (cg-RX-API-DMAC10.html)
ES (1) ES2952723T3 (cg-RX-API-DMAC10.html)
GB (2) GB201505239D0 (cg-RX-API-DMAC10.html)
MX (1) MX392158B (cg-RX-API-DMAC10.html)
RU (1) RU2729491C2 (cg-RX-API-DMAC10.html)
WO (1) WO2016156803A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2539161A (en) * 2014-11-26 2016-12-14 Neuro-Bio Ltd Neurodegenerative disorders
GB2546773B (en) * 2016-01-28 2020-06-17 Neuro Bio Ltd Cancer
GB201705044D0 (en) * 2017-03-29 2017-05-10 Neuro-Bio Ltd Biomarker
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
GB202112831D0 (en) * 2021-09-09 2021-10-27 Neuro Bio Ltd Biomarker
GB202113941D0 (en) 2021-09-29 2021-11-10 Neuro Bio Ltd Skin biomarker
EP4584388A1 (en) 2022-09-08 2025-07-16 Neuro-Bio Ltd Lateral flow device for diagnosing alzheimer's disease using the t14 peptide
GB202308799D0 (en) 2023-06-13 2023-07-26 Neuro Bio Ltd Neurodegenerative disease
GB202308779D0 (en) * 2023-06-13 2023-07-26 Neuro Bio Ltd Aptamer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606040D0 (en) * 1996-03-22 1996-05-22 Isis Innovation Active peptide
US20040038875A1 (en) 2000-03-29 2004-02-26 Greenfield Susan Adele Alpha 7nicotinic receptor screening assays
GB0028578D0 (en) * 2000-11-23 2001-01-10 Synaptica Ltd Screening assays
GB0502068D0 (en) * 2005-02-01 2005-03-09 King S College London Screening method
BRPI0615997A8 (pt) * 2005-08-16 2018-05-22 Genentech Inc método para prever a sensibilidade de uma amostra de célula ou tecido, método para induzir apoptose em uma amostra de célula ou tecido e método de tratamento de uma disfunção
GB0708646D0 (en) * 2007-05-04 2007-06-13 Enkephala Ltd Biologically active C-terminal fragment of acetylcholinesterase
WO2009040789A2 (en) * 2007-09-24 2009-04-02 Technion Research & Development Foundation Ltd. T cell subpopulations capable of treating cancer
CN101530162B (zh) * 2008-03-10 2011-11-23 北京大北农科技集团股份有限公司 一种新型蛋白饲料添加剂的制备方法

Also Published As

Publication number Publication date
US20180051094A1 (en) 2018-02-22
US10954306B2 (en) 2021-03-23
WO2016156803A1 (en) 2016-10-06
RU2017133649A3 (cg-RX-API-DMAC10.html) 2020-02-17
GB2541477A (en) 2017-02-22
JP7327897B2 (ja) 2023-08-16
RU2017133649A (ru) 2019-04-29
MX392158B (es) 2025-03-21
CA2979972A1 (en) 2016-10-06
AU2016240020A1 (en) 2017-11-02
KR20170138414A (ko) 2017-12-15
JP2018516849A (ja) 2018-06-28
RU2729491C2 (ru) 2020-08-07
MX2017012397A (es) 2018-01-26
ES2952723T3 (es) 2023-11-03
EP3274371B1 (en) 2023-06-07
CN107531796A (zh) 2018-01-02
AU2016240020B2 (en) 2022-02-17
KR102626626B1 (ko) 2024-01-17
GB201600871D0 (en) 2016-03-02
EP3274371A1 (en) 2018-01-31
BR112017020769A2 (en) 2018-06-26

Similar Documents

Publication Publication Date Title
IL259048A (en) Antibodies against ror-1
SG10201912570UA (en) Anti-garp antibody
SG10201913864RA (en) Anti-LAG-3 Antibodies
IL253633B (en) Anti-transthyretin antibodies
SG10202010735PA (en) Tau-binding antibodies
GB201521393D0 (en) Antibodies
SG11201706126WA (en) Anti-transthyretin antibodies
GB201521382D0 (en) Antibodies
IL255323A0 (en) Anti-fcrn antibodies
IL268889A (en) Anti-EPHA4 antibody
GB201515351D0 (en) Antibody
GB201600871D0 (en) Antibody
HUE057499T2 (hu) Antitest
SG10201913748QA (en) Antibody
GB201503438D0 (en) Antibodies
GB201522394D0 (en) Antibodies
IL284022B1 (en) Anti-transthyretin antibodies
GB201513447D0 (en) Antibody
GB201518728D0 (en) Antibodies
GB201515572D0 (en) Anti-LAG-3 antibodies
GB201514425D0 (en) Antibodies
GB201508444D0 (en) Antibodies
GB201508437D0 (en) Antibodies
GB201507541D0 (en) Antibodies
GB201504858D0 (en) Antibodies

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)